Table 3.
Biochemical | Super Pathway | Sub Pathway | Metabolite | PLS-DA Effect Size | Spearman r | Spearman p-Value |
---|---|---|---|---|---|---|
Pregnen-diol disulfate * | Lipid | Pregnenolone steroids | 32,562 | 0.249 | 0.333 | 0.018 |
1-stearoyl-GPS (18:0) * | Lipid | Lysophospholipid | 45,966 | −0.253 | −0.283 | 0.047 |
1,3-dimethylurate | Xenobiotics | Xanthine metabolism | 32,391 | −0.090 | −0.292 | 0.040 |
2-deoxyuridine | Nucleotide | Pyrimidine metabolism, uracil containing | 52,602 | 0.262 | 0.344 | 0.015 |
Serotonin | Amino acid | Tryptophan metabolism | 2342 | −0.059 | −0.316 | 0.025 |
Inosine 5-monophosphate (IMP) | Nucleotide | Purine metabolism, (hypo)xanthine/inosine containing | 2133 | −0.174 | −0.396 | 0.004 |
1-stearoyl-2-oleoyl-GPS (18:0/18:1) | Lipid | Phosphatidylserine (PS) | 19265 | −0.192 | −0.391 | 0.005 |
Cysteine-glutathione disulfide | Amino acid | Glutathione metabolism | 35,159 | −0.074 | −0.288 | 0.042 |
2-hydroxy-4-(methylthio)butanoic acid | Amino acid | Methionine, cysteine, SAM, and taurine metabolism | 63,739 | 0.109 | 0.299 | 0.035 |
AMP | Nucleotide | Purine metabolism, adenine containing | 32,342 | −0.204 | −0.503 | 0.0002 |
9,10-diHOME | Lipid | Fatty acid, dihydroxy | 38,399 | 0.213 | 0.454 | 0.001 |
6-oxopiperidine-2-carboxylate | Amino acid | Lysine metabolism | 43,231 | 0.227 | 0.280 | 0.049 |
Octadecanedioylcarnitine (C18-DC) * | Lipid | Fatty acid metabolism (Acyl carnitine, dicarboxylate) | 61,867 | 0.134 | 0.375 | 0.007 |
S-methylcysteine sulfoxide | Amino acid | Methionine, cysteine, SAM, and taurine metabolism | 43,378 | −0.004 | −0.317 | 0.025 |
Table 3 displays microbial metabolites that satisfied the following conditions: (1) they were significantly different between participants with and without FIB-4 ≥ 1.45 (as determined by Wilcoxon test); (2) they had an absolute difference >0.5 determined via volcano plot; (3) they were found to contribute most to class separation by PLS-DA; and (4) they correlated with FIB-4 score via Spearman’s correlation. 1 FIB-4 score ≥ 1.45 was defined as “unable to exclude advanced liver fibrosis/cirrhosis”. Rows in light grey indicate FIB-4 < 1.45 and rows in dark grey indicate FIB-4 ≥ 1.45. * Indicates a compound that has not been confirmed based on a standard, but Metabolon Inc. is confident in its identity. Abbreviation: PLS-DA, partial least squares-discriminant analysis.